Table 2 Meta-analysis between the PON1 rs662 polymorphism and plasma lipid levels
Groups or subgroups | Comparisons (Subjects) | SMD (95% CI) | P Heterogeneity | P SMD |
|---|---|---|---|---|
TG | ||||
 All | 91 (24,704) | 0.06 (0.01–0.11) | < 0.01 | 0.02 |
 Studies in HWE | 64 (20,340) | 0.06 (0.00–0.12) | < 0.01 | 0.04 |
 Male | 5 (3322) | −0.01 (− 0.26–0.24) | < 0.01 | 0.93 |
 Female | 6 (1210) | 0.10 (−0.04–0.25) | 0.73 | 0.15 |
 Caucasian | 32 (11,555) | 0.06 (−0.01–0.13) | < 0.01 | 0.08 |
 Asian | 35 (7659) | 0.12 (0.00–0.23) | < 0.01 | 0.04 |
 African | 6 (1880) | 0.03 (−0.09–0.15) | 0.94 | 0.58 |
 Other ethnicity | 18 (3610) | −0.00 (− 0.10–0.10) | 0.02 | 0.98 |
 CHD | 16 (3912) | 0.10 (0.04–0.17) | < 0.01 | < 0.01 |
 T2DM | 10 (1715) | 0.18 (0.07–0.28) | 0.03 | < 0.01 |
 Hyperlipidemia | 3 (296) | −0.13 (− 0.43–0.17) | 0.66 | 0.39 |
 Healthy or control | 36 (8693) | 0.03 (−0.02–0.08) | 0.30 | 0.22 |
TC | ||||
 All | 103 (33,696) | 0.04 (0.00–0.07) | <  0.01 | 0.05 |
 Studies in HWE | 75 (27,792) | 0.03 (−0.01–0.07) | <  0.01 | 0.13 |
 Male | 5 (4354) | −0.03 (− 0.09–0.03) | 0.58 | 0.26 |
 Female | 4 (914) | 0.19 (−0.03–0.40) | 0.24 | 0.09 |
 Caucasian | 46 (19,714) | 0.01 (−0.03–0.05) | 0.01 | 0.65 |
 Asian | 36 (7869) | 0.14 (0.05–0.24) | < 0.01 | < 0.01 |
 African | 3 (1051) | 0.10 (−0.15–0.35) | 0.22 | 0.42 |
 Other ethnicity | 18 (5062) | −0.02 (− 0.10–0.07) | 0.07 | 0.68 |
 CHD | 19 (5995) | 0.01 (−0.05–0.06) | 0.58 | 0.84 |
 T2DM | 12 (2213) | 0.12 (−0.04–0.28) | < 0.01 | 0.14 |
 Hyperlipidemia | 3 (296) | −0.16 (− 0.46–0.14) | 0.75 | 0.29 |
 Healthy or control | 40 (11,168) | 0.07 (0.01–0.14) | <  0.01 | 0.04 |
LDL-C | ||||
 All | 94 (34,757) | 0.04 (0.00–0.08) | <  0.01 | 0.04 |
 Studies in HWE | 73 (31,416) | 0.04 (0.00–0.09) | < 0.01 | 0.04 |
 Male | 4 (1570) | 0.10 (−0.22–0.02) | 0.72 | 0.08 |
 Female | 4 (914) | 0.26 (0.01–0.51) | 0.12 | 0.04 |
 Caucasian | 41 (21,056) | 0.01 (−0.03–0.05) | 0.01 | 0.49 |
 Asian | 31 (7034) | 0.13 (0.01–0.26) | <  0.01 | 0.04 |
 African | 4 (1605) | 0.12 (−0.17–0.40) | 0.02 | 0.43 |
 Other ethnicity | 18 (5062) | 0.02 (−0.08–0.12) | 0.01 | 0.69 |
 CHD | 16 (5148) | −0.01 (− 0.06–0.05) | 0.45 | 0.85 |
 T2DM | 8 (1446) | 0.36 (0.03–0.69) | <  0.01 | 0.03 |
 Hyperlipidemia | 4 (399) | −0.09 (− 0.34–0.16) | 0.56 | 0.48 |
 Healthy or control | 39 (12,230) | 0.06 (0.00–0.13) | < 0.01 | 0.05 |
HDL-C | ||||
 All | 116 (40,336) | −0.01 (−0.05–0.04) | <  0.01 | 0.68 |
 Studies in HWE | 87 (34,743) | −0.01 (− 0.05–0.04) | <  0.01 | 0.78 |
 Male | 7 (3729) | 0.03 (−0.05–0.11) | 0.28 | 0.51 |
 Female | 7 (2724) | −0.01 (− 0.09–0.07) | 0.63 | 0.78 |
 Caucasian | 54 (26,409) | −0.03 (− 0.08–0.02) | <  0.01 | 0.22 |
 Asian | 35 (7802) | 0.08 (−0.06–0.22) | < 0.01 | 0.25 |
 African | 8 (2180) | −0.01 (− 0.17–0.14) | 0.09 | 0.90 |
 Other ethnicity | 19 (3945) | −0.02 (− 0.12–0.09) | < 0.01 | 0.76 |
 CHD | 18 (5355) | −0.06 (− 0.12−− 0.01) | 0.01 | 0.02 |
 T2DM | 13 (2328) | -0.01 (− 0.09–0.08) | 0.62 | 0.91 |
 Hyperlipidemia | 3 (296) | 0.11 (−0.19–0.41) | 0.55 | 0.48 |
 Healthy or control | 47 (15,342) | 0.02 (−0.01–0.06) | <  0.01 | 0.21 |